Axsome Therapeutics (0HKF) Share Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0HKF Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Axsome

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0HKF Stock 12 Month Forecast

Average Price Target

$291.00

▲(41.74% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $291.00 with a high forecast of $380.00 and a low forecast of $251.00. The average price target represents a 41.74% change from the last price of $205.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"120":"$120","381":"$381","185.25":"$185.3","250.5":"$250.5","315.75":"$315.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":291,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$291.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":251,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$251.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[120,185.25,250.5,315.75,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205.3,218.73846153846154,232.1769230769231,245.6153846153846,259.05384615384617,272.4923076923077,285.9307692307692,299.36923076923074,312.8076923076923,326.24615384615385,339.68461538461537,353.12307692307695,366.5615384615385,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205.3,211.8923076923077,218.48461538461538,225.0769230769231,231.66923076923078,238.26153846153846,244.85384615384615,251.44615384615383,258.03846153846155,264.63076923076926,271.2230769230769,277.81538461538463,284.4076923076923,{"y":291,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205.3,208.81538461538463,212.33076923076925,215.84615384615387,219.36153846153846,222.87692307692308,226.3923076923077,229.90769230769232,233.42307692307693,236.93846153846155,240.45384615384614,243.96923076923076,247.48461538461538,{"y":251,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":121.113,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.935,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.141,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.057,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.635,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.31,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.3,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$380.00

Average Price Target$291.00

Lowest Price Target$251.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Benjamin Burnett

Wells Fargo

$256

Buy

24.70%

Upside

Reiterated

09/02/26

Analysts Are Bullish on Top Healthcare Stocks: OmniAb (OABI), Cabaletta Bio (CABA)

Leonid Timashev

RBC Capital

$297

Buy

44.67%

Upside

Assigned

09/01/26

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)

Ram Selvaraju

H.C. Wainwright

$290

Buy

41.26%

Upside

Reiterated

08/31/26

Axsome pullback brings attractive entry point, says H.C. WainwrightAxsome pullback brings attractive entry point, says H.C. Wainwright

David Amsellem

Piper Sandler

$258

Buy

25.67%

Upside

Reiterated

08/18/26

Piper Sandler Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Graig Suvannavejh

Mizuho Securities

$306→$316

Buy

53.92%

Upside

Reiterated

08/12/26

Axsome Therapeutics (AXSM) Receives a Buy from Mizuho Securities

Andrew Tsai

Jefferies

$380

Buy

85.09%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/10/26

Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook

Ami Fadia

Needham

$267→$268

Buy

30.54%

Upside

Reiterated

08/10/26

Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure

Yatin Suneja

Guggenheim

$260→$275

Buy

33.95%

Upside

Reiterated

08/10/26

Axsome Therapeutics price target raised to $275 from $260 at GuggenheimAxsome Therapeutics price target raised to $275 from $260 at Guggenheim

Jason Gerberry

Bank of America Securities

$276

Buy

34.44%

Upside

Reiterated

08/10/26

Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating

Joseph Thome

TD Cowen

$300→$315

Buy

53.43%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (NASDAQ: HRTX), Aquestive Therapeutics (NASDAQ: AQST) and Axsome Therapeutics (NASDAQ: AXSM)

Sean Laaman

Morgan Stanley

$242→$251

Hold

22.26%

Upside

Reiterated

08/10/26

Axsome Therapeutics (AXSM) Receives a Hold from Morgan Stanley

Malcolm Hoffman

BMO Capital

$310

Buy

51.00%

Upside

Reiterated

08/10/26

Analyst Reiterates Buy on Axsome, Sees Undervalued Pipeline Upside with Unchanged $310 Price Target

David Hoang

Deutsche Bank

$281→$280

Buy

36.39%

Upside

Assigned

05/05/26

Axsome Therapeutics price target raised to $281 from $245 at Deutsche BankAxsome Therapeutics price target raised to $281 from $245 at Deutsche Bank

Brian Skorney

Robert W. Baird

$241→$246

Buy

19.82%

Upside

Reiterated

05/05/26

Axsome Therapeutics price target raised to $246 from $241 at BairdAxsome Therapeutics price target raised to $246 from $241 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Benjamin Burnett

Wells Fargo

$256

Buy

24.70%

Upside

Reiterated

09/02/26

Analysts Are Bullish on Top Healthcare Stocks: OmniAb (OABI), Cabaletta Bio (CABA)

Leonid Timashev

RBC Capital

$297

Buy

44.67%

Upside

Assigned

09/01/26

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)

Ram Selvaraju

H.C. Wainwright

$290

Buy

41.26%

Upside

Reiterated

08/31/26

Axsome pullback brings attractive entry point, says H.C. WainwrightAxsome pullback brings attractive entry point, says H.C. Wainwright

David Amsellem

Piper Sandler

$258

Buy

25.67%

Upside

Reiterated

08/18/26

Piper Sandler Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Graig Suvannavejh

Mizuho Securities

$306→$316

Buy

53.92%

Upside

Reiterated

08/12/26

Axsome Therapeutics (AXSM) Receives a Buy from Mizuho Securities

Andrew Tsai

Jefferies

$380

Buy

85.09%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/10/26

Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook

Ami Fadia

Needham

$267→$268

Buy

30.54%

Upside

Reiterated

08/10/26

Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure

Yatin Suneja

Guggenheim

$260→$275

Buy

33.95%

Upside

Reiterated

08/10/26

Axsome Therapeutics price target raised to $275 from $260 at GuggenheimAxsome Therapeutics price target raised to $275 from $260 at Guggenheim

Jason Gerberry

Bank of America Securities

$276

Buy

34.44%

Upside

Reiterated

08/10/26

Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating

Joseph Thome

TD Cowen

$300→$315

Buy

53.43%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (NASDAQ: HRTX), Aquestive Therapeutics (NASDAQ: AQST) and Axsome Therapeutics (NASDAQ: AXSM)

Sean Laaman

Morgan Stanley

$242→$251

Hold

22.26%

Upside

Reiterated

08/10/26

Axsome Therapeutics (AXSM) Receives a Hold from Morgan Stanley

Malcolm Hoffman

BMO Capital

$310

Buy

51.00%

Upside

Reiterated

08/10/26

Analyst Reiterates Buy on Axsome, Sees Undervalued Pipeline Upside with Unchanged $310 Price Target

David Hoang

Deutsche Bank

$281→$280

Buy

36.39%

Upside

Assigned

05/05/26

Axsome Therapeutics price target raised to $281 from $245 at Deutsche BankAxsome Therapeutics price target raised to $281 from $245 at Deutsche Bank

Brian Skorney

Robert W. Baird

$241→$246

Buy

19.82%

Upside

Reiterated

05/05/26

Axsome Therapeutics price target raised to $246 from $241 at BairdAxsome Therapeutics price target raised to $246 from $241 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

BLTEBelite Bio, Inc. ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

3 Months

Joon LeeTruist Financial

Success Rate

19/27 ratings generated profit

Average Return

+15.15%

Copying Joon Lee's trades and holding each position for 3 Months would result in 70.37% of your transactions generating a profit, with an average return of +15.15% per trade.

1 Year

Marc GoodmanLeerink Partners

Success Rate

31/32 ratings generated profit

Average Return

+62.13%

Copying Marc Goodman's trades and holding each position for 1 Year would result in 96.88% of your transactions generating a profit, with an average return of +62.13% per trade.

2 Years

Marc GoodmanLeerink Partners

Success Rate

32/32 ratings generated profit

Average Return

+107.05%

Copying Marc Goodman's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +107.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HKF Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0HKF has received 26 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0HKF average Analyst price target in the past 3 months is 291.00.

Each month's total comprises the sum of three months' worth of ratings.

0HKF Financial Forecast

0HKF Earnings Forecast

Next quarter’s earnings estimate for 0HKF is -$0.49 with a range of -$1.00 to -$0.03. The previous quarter’s EPS was -$0.99. 0HKF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HKF has Performed in-line its overall industry.

0HKF Sales Forecast

Next quarter’s sales forecast for 0HKF is $258.26M with a range of $227.87M to $281.90M. The previous quarter’s sales results were $218.38M. 0HKF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HKF has Performed in-line its overall industry.

0HKF Stock Forecast FAQ

What is GB:0HKF’s average 12-month price target, according to analysts?

Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 291.00.

What is GB:0HKF’s upside potential, based on the analysts’ average price target?

Axsome Therapeutics Inc has 41.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Axsome Therapeutics Inc a Buy, Sell or Hold?

Axsome Therapeutics Inc has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Axsome Therapeutics Inc’s share price target?

The average share price target for Axsome Therapeutics Inc is 291.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $380.00 ,and the lowest forecast is $251.00. The average share price target represents 41.74% Increase from the current price of $205.3.

What do analysts say about Axsome Therapeutics Inc?

Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Axsome Therapeutics Inc?

To buy shares of GB:0HKF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Axsome Therapeutics (0HKF) Share Forecast & Price Target

0HKF Analyst Ratings

0HKF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Axsome Therapeutics

0HKF Analyst Recommendation Trends

0HKF Financial Forecast

0HKF Earnings Forecast

0HKF Sales Forecast

0HKF Stock Forecast FAQ

Detailed List of Analyst Forecasts